Amprion

EQS-News: Amprion GmbH: Invitation to the 2023 annual results conference call for investors and analysts

Retrieved on: 
Wednesday, April 10, 2024
Annual report, Amprion

Amprion GmbH will publish its annual report for the financial year 2023 on Thursday, 11th April 2024.

Key Points: 
  • Amprion GmbH will publish its annual report for the financial year 2023 on Thursday, 11th April 2024.
  • On this occasion we cordially invite you to our:
    Peter Rüth, Chief Financial Officer of Amprion GmbH, will present the annual results for the financial year 2023 and will provide further insights into the business development.
  • The conference call will be held in English.
  • A recording of the call will be made available after the event on our corporate website.

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 27, 2024
Research, Neurodegenerative disease, Notifiable disease, LDL, Obesity, University, Comparison, PCSK9, Central Florida, Translational research, COVID-19, PD, CSF, Diabetes, Amprion, Patient, CNS, Mayo Clinic, Vaccine, Journal, Biomarker, Travel, Myostatin, Hope, SARS-CoV-2, D&O, Investment, Solid lipid nanoparticle, MDS, Marketing, Parkinson's disease, Hypercholesterolemia

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • We also seek to advance UB-311, our anti-Aβ Alzheimer’s candidate, as we resume dialogue with regulatory authorities and partners.
  • General and administrative expenses were $3.4 million and $7.7 million for the three months ended December 31, 2023, and 2022, respectively.
  • General and administrative expenses were $22.4 million and $28.4 million for the years ended December 31, 2023, and 2022, respectively.

EQS-News: Dr Christoph Müller is appointed to the Amprion Management Board

Retrieved on: 
Wednesday, December 27, 2023
Supervisory board, Economics, Tigges, Amprion, Doctor of Philosophy, E.ON UK, Noteć, Brick, EnBW

Dr Christoph Müller will then take over the function of CEO.

Key Points: 
  • Dr Christoph Müller will then take over the function of CEO.
  • At its meeting yesterday, the Supervisory Board of Amprion GmbH appointed Dr Christoph Müller to the company’s Management Board with effect from 1 July 2024.
  • The current Chairman of the Management Board at Netze BW will take over the function of CEO of Amprion GmbH on 1 January 2025 from Dr Hans-Jürgen Brick when he retires as planned.
  • “I’m proud of what we have achieved together at Amprion over the past few years and look forward to working with Christoph Müller.

EQS-News: Amprion GmbH: Amprion again achieves excellent ESG rating by Sustainalytics

Retrieved on: 
Monday, September 18, 2023
Electric utility, ESG, Environment, GRI, Sustainalytics, Classification, Amprion, Cryptocurrency, Renewable energy

The transmission system operator Amprion has once again significantly improved its ESG rating compared to the previous year.

Key Points: 
  • The transmission system operator Amprion has once again significantly improved its ESG rating compared to the previous year.
  • The rating of the renowned agency Sustain-alytics is now 9.6.
  • Amprion has again received an excellent ESG rating from the renowned rating agency Sustainalytics.
  • "The excellent ESG-rating from Sustainalytics is the result of excellent sustainability management as well as the overall business performance.

EQS-News: Amprion GmbH: Amprion again successful with green bond in volume of €1.2 billion

Retrieved on: 
Wednesday, August 30, 2023
Luxembourg Stock Exchange, Bayerische Landesbank, Moody's Investors Service, UniCredit, Commerzbank, ING, DZ, Fitch, Landesbank, Sustainalytics, Euro, Investment, LBBW, SEB, BANK, CFO, ESG, DZ BANK AG, Security (finance), Renewable energy, Marketing, Amprion

The transmission system operator Amprion has once again successfully placed a green bond with a total nominal volume of €1.2 billion on the international capital market.

Key Points: 
  • The transmission system operator Amprion has once again successfully placed a green bond with a total nominal volume of €1.2 billion on the international capital market.
  • The green dual-tranche bond was issued within Amprion's €9 billion debt issuance programme.
  • The second tranche with a volume of €700 million has a maturity of 11 years and an interest coupon of 4.125% p. a.
    Peter Rüth, CFO of Amprion: “We have once again successfully placed a dual-tranche green bond.
  • Moody's has assigned a Baa1 rating to the newly issued dual-tranche green bond.

EQS-News: Amprion GmbH: Amprion presents solid figures for the first half of 2023 and first “Green Finance Investor Report”

Retrieved on: 
Tuesday, August 22, 2023
Electricity, Finance Secretary (India), EBITDA, BDO, Investment, CFO, Growth, GBP, 2005 German federal election, Security (finance), Renewable energy, Amprion

The transmission system operator Amprion has published solid figures for the first half of 2023 and its first Green Finance Investor Report.

Key Points: 
  • The transmission system operator Amprion has published solid figures for the first half of 2023 and its first Green Finance Investor Report.
  • The company thus increases transparency for its investors and underlines its ambitions to continue issuing sustainable finance instruments in the future.
  • Amprion reports revenues of around €2.9 billion for the first half of 2023, an increase of almost 90 percent compared to previous year’s period.
  • Peter Rüth, CFO of Amprion: “Amprion has achieved solid results in the first half of 2023 despite the persistently challenging conditions.

Amprion Announces Granting of European Patents for Seed Amplification Assay Platform

Retrieved on: 
Tuesday, August 15, 2023
Patent, PrP, Intellectual property, CAP, Neurodegenerative disease, Clinical trial, Sutro Biopharma, SAA, Lead, University, Research, CLIA, Laboratory, SAN, Alpha-synuclein, Diagnosis, PMCA, Fine chemical, Nursing, EU, Amprion

SAN DIEGO, Aug. 15, 2023 /PRNewswire/ -- Amprion, a global leader in neurodegenerative disease diagnostics, continues to fortify its Intellectual Property surrounding the company's proprietary methodology for highly sensitive detection of misfolded proteins and amyloid-like aggregates. Recently, fundamental patents have been issued in the EU and UK which expands Amprion's extensive coverage in key geographies. The issued patents apply broadly to the methodology known alternatively as Seed Amplification Assay (SAA), Protein Misfolding Cyclic Amplification (PMCA) and Real-Time Quaking-Induced Conversion (RT-QuiC).  

Key Points: 
  • Recently, fundamental patents have been issued in the EU and UK which expands Amprion's extensive coverage in key geographies.
  • The issued patents apply broadly to the methodology known alternatively as Seed Amplification Assay (SAA), Protein Misfolding Cyclic Amplification (PMCA) and Real-Time Quaking-Induced Conversion (RT-QuiC).
  • Amprion is the only entity, commercial or otherwise, that has issued patents in each of the major misfolded protein categories.
  • Amprion plans to lead and perform all clinical trial collaborations to ensure the highest degree of quality and consistent performance needed by Biopharma partners.

EQS-News: Amprion GmbH: Fitch Ratings confirms “BBB+” rating with stable outlook for Amprion

Retrieved on: 
Saturday, June 10, 2023
Amprion, Fitch Ratings, Investment, Renewable energy

The transmission system operator Amprion GmbH (“Amprion”) has again received a “BBB+” rating with a stable outlook from the rating agency Fitch Ratings as part of its annual review.

Key Points: 
  • The transmission system operator Amprion GmbH (“Amprion”) has again received a “BBB+” rating with a stable outlook from the rating agency Fitch Ratings as part of its annual review.
  • This reflects Amprion’s very strong credit quality.
  • This is once again underlined by the confirmation of the investment grade rating.
  • Amprion plans to invest 22.2 billion euro in the expansion and renewal of the transmission grid in Germany within the next five years.

EQS-News: Amprion GmbH: Amprion receives outstanding ESG ratings from Sustainable Fitch

Retrieved on: 
Thursday, May 11, 2023
Electricity, ESG, Environment, Risk management, Sustainalytics, Renewable energy, Amprion

The ratings assess Amprion's corporate performance, its Green Finance Framework as well as its green bonds for the first time

Key Points: 
  • The ratings assess Amprion's corporate performance, its Green Finance Framework as well as its green bonds for the first time
    The transmission system operator Amprion has received its first ESG ratings from the renowned rating agency Sustainable Fitch.
  • Sustainable Fitch conducts an assessment of the company's sustainability performance, green finance framework and outstanding green financial instruments for each rating.
  • Sustainable Fitch's ratings are assigned on a scale of one to five, with a rating of "1" representing full compliance with ESG best practices.
  • In addition to Sustainable Fitch, Amprion is also rated by the rating agency Sustainalytics in the area of sustainability.

Amprion Announces Presentation of Findings Related to Usage of the αSynuclein Seed Amplification Assay in Recent Parkinson's Study at 2023 AAN Annual Meeting

Retrieved on: 
Friday, April 21, 2023
LDT, University, Lancet Neurology, Disease, AAN, The Michael J. Fox Foundation, Convention, Pathology, SAA, Multiple system atrophy, American Academy, EST, Research, Lewy, Biomarker, Neurology, Cerebrospinal fluid, Parkinson's disease, National Primate Research Exhibition Hall, MJFF, Physician, Patient, SAN, Laboratory developed test, Diagnosis, Ageing, American Academy of Neurology, The Lancet, Synucleinopathy, Alzheimer's disease, Pharmaceutical industry, Nightclub, Amprion

SAN DIEGO, April 21, 2023 /PRNewswire/ -- Amprion is pleased to announce that it will attend the American Academy of Neurology (AAN) Annual Meeting in Boston April 22-27 to share insights about its SYNTap Biomarker Test, a first-in-class qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid physicians in diagnosing synucleinopathies.

Key Points: 
  • To learn more about SYNTap during the meeting, attendees can visit the Exhibit Hall to:
    Meet with the Amprion team in Booth 668.
  • Attend Dr. Andrew Siderowf's presentation at 2 p.m. EST on Monday, April 24 on the Emerging Neurologic Care Presentation Stage.
  • The talk is titled "High Diagnostic Accuracy of Amprion's SAA Assay Informs PD Heterogeneity and Disease Onset in Analysis of the PPMI Cohort."
  • In his presentation, Dr. Siderowf will discuss how Amprion's αSyn Seed Amplification Assay was utilized in the landmark PPMI paper, which was published in The Lancet Neurology journal on April 12, 2023.